203 related articles for article (PubMed ID: 14573867)
1. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
Leonidas DD; Chavali GB; Oikonomakos NG; Chrysina ED; Kosmopoulou MN; Vlassi M; Frankling C; Acharya KR
Protein Sci; 2003 Nov; 12(11):2559-74. PubMed ID: 14573867
[TBL] [Abstract][Full Text] [Related]
2. Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1999 Aug; 38(32):10287-97. PubMed ID: 10441122
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 A resolution.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1997 May; 36(18):5578-88. PubMed ID: 9154942
[TBL] [Abstract][Full Text] [Related]
4. Mapping the ribonucleolytic active site of eosinophil-derived neurotoxin (EDN). High resolution crystal structures of EDN complexes with adenylic nucleotide inhibitors.
Leonidas DD; Boix E; Prill R; Suzuki M; Turton R; Minson K; Swaminathan GJ; Youle RJ; Acharya KR
J Biol Chem; 2001 May; 276(18):15009-17. PubMed ID: 11154698
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of eosinophil cationic protein in complex with 2',5'-ADP at 2.0 A resolution reveals the details of the ribonucleolytic active site.
Mohan CG; Boix E; Evans HR; Nikolovski Z; Nogués MV; Cuchillo CM; Acharya KR
Biochemistry; 2002 Oct; 41(40):12100-6. PubMed ID: 12356310
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor design for ribonuclease A: the binding of two 5'-phosphate uridine analogues.
Tsirkone VG; Dossi K; Drakou C; Zographos SE; Kontou M; Leonidas DD
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Jul; 65(Pt 7):671-7. PubMed ID: 19574636
[TBL] [Abstract][Full Text] [Related]
7. Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy.
Tonan K; Xu P; Jenkins JL; Russo A; Shapiro R; Ni F
Biochemistry; 2003 Sep; 42(38):11137-49. PubMed ID: 14503864
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of eosinophil-derived neurotoxin (EDN) in complex with the inhibitors 5'-ATP, Ap3A, Ap4A, and Ap5A.
Baker MD; Holloway DE; Swaminathan GJ; Acharya KR
Biochemistry; 2006 Jan; 45(2):416-26. PubMed ID: 16401072
[TBL] [Abstract][Full Text] [Related]
9. Influence of naturally-occurring 5'-pyrophosphate-linked substituents on the binding of adenylic inhibitors to ribonuclease a: an X-ray crystallographic study.
Holloway DE; Chavali GB; Leonidas DD; Baker MD; Acharya KR
Biopolymers; 2009 Dec; 91(12):995-1008. PubMed ID: 19191310
[TBL] [Abstract][Full Text] [Related]
10. A combined kinetic and modeling study of the catalytic center subsites of human angiogenin.
Russo N; Acharya KR; Vallee BL; Shapiro R
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):804-8. PubMed ID: 8570639
[TBL] [Abstract][Full Text] [Related]
11. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
Leonidas DD; Shapiro R; Allen SC; Subbarao GV; Veluraja K; Acharya KR
J Mol Biol; 1999 Jan; 285(3):1209-33. PubMed ID: 9918722
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of eosinophil cationic protein at 2.4 A resolution.
Boix E; Leonidas DD; Nikolovski Z; Nogués MV; Cuchillo CM; Acharya KR
Biochemistry; 1999 Dec; 38(51):16794-801. PubMed ID: 10606511
[TBL] [Abstract][Full Text] [Related]
13. Triazole pyrimidine nucleosides as inhibitors of Ribonuclease A. Synthesis, biochemical, and structural evaluation.
Parmenopoulou V; Chatzileontiadou DS; Manta S; Bougiatioti S; Maragozidis P; Gkaragkouni DN; Kaffesaki E; Kantsadi AL; Skamnaki VT; Zographos SE; Zounpoulakis P; Balatsos NA; Komiotis D; Leonidas DD
Bioorg Med Chem; 2012 Dec; 20(24):7184-93. PubMed ID: 23122937
[TBL] [Abstract][Full Text] [Related]
14. The binding of IMP to ribonuclease A.
Hatzopoulos GN; Leonidas DD; Kardakaris R; Kobe J; Oikonomakos NG
FEBS J; 2005 Aug; 272(15):3988-4001. PubMed ID: 16045769
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mammalian ribonucleases by endogenous adenosine dinucleotides.
Kumar K; Jenkins JL; Jardine AM; Shapiro R
Biochem Biophys Res Commun; 2003 Jan; 300(1):81-6. PubMed ID: 12480524
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional structure of a human pancreatic ribonuclease variant, a step forward in the design of cytotoxic ribonucleases.
Pous J; Canals A; Terzyan SS; Guasch A; Benito A; Ribó M; Vilanova M; Coll M
J Mol Biol; 2000 Oct; 303(1):49-60. PubMed ID: 11021969
[TBL] [Abstract][Full Text] [Related]
17. Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography.
Leonidas DD; Chavali GB; Jardine AM; Li S; Shapiro R; Acharya KR
Protein Sci; 2001 Aug; 10(8):1669-76. PubMed ID: 11468363
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A.
Kobe B; Deisenhofer J
J Mol Biol; 1996 Dec; 264(5):1028-43. PubMed ID: 9000628
[TBL] [Abstract][Full Text] [Related]
19. Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity.
Boix E; Nikolovski Z; Moiseyev GP; Rosenberg HF; Cuchillo CM; Nogués MV
J Biol Chem; 1999 May; 274(22):15605-14. PubMed ID: 10336457
[TBL] [Abstract][Full Text] [Related]
20. Molecular recognition of human eosinophil-derived neurotoxin (RNase 2) by placental ribonuclease inhibitor.
Iyer S; Holloway DE; Kumar K; Shapiro R; Acharya KR
J Mol Biol; 2005 Apr; 347(3):637-55. PubMed ID: 15755456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
